RESEARCH FIELD
3D1015
Back3D1015
177Lu-PSMA-3D1015
3D Medicines owns a next-generation RDC (Radionuclide Drug Conjugate) product with fully independent global intellectual property rights.
Differentiated Advantages of 3D1015
- High exposure and prolonged retention in tumor tissues
- Potent tumor inhibition efficacy
- Favorable safety and tolerability profile
- Low radionuclide consumption
3D1015 presented its latest IIT study data at the 2026 AACR Annual Meeting
